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ABSTRACT
Objective: To provide context for the malignancy
experience in the rheumatoid arthritis (RA) abatacept
clinical development programme (CDP) by performing
comparisons with similar RA patients and the general
population.
Methods: Malignancy outcomes included total malig-
nancy (excluding non-melanoma skin cancer (NMSC)),
breast, colorectal, lung cancers and lymphoma.
Comparisons were made between the observed incidence
in patients within the abatacept CDP and RA patients on
disease-modifying antirheumatic drugs (DMARD) identi-
fied from five data sources: the population-based British
Columbia RA Cohort, the Norfolk Arthritis Register, the
National Data Bank for Rheumatic Diseases, the Sweden
Early RA Register and the General Practice Research
Database. Age and sex-adjusted incidence rates (IR) and
standardised incidence ratios (SIR) were used to compare
events in the abatacept trials with the RA DMARD
cohorts and the general population.
Results: A total of 4134 RA patients treated with
abatacept in seven trials and 41 529 DMARD-treated RA
patients in the five observational cohorts was identified
for study inclusion. In the abatacept-treated patients, the
51 malignancies (excluding NMSC), seven cases of
breast, two cases of colorectal, 13 cases of lung cancer
and five cases of lymphoma observed were not greater
than the range of expected cases from the five RA
cohorts. The SIR comparing RA patients with the general
population were consistent with those reported in the
literature.
Conclusions: The IR of total malignancy (excluding
NMSC), breast, colorectal, lung cancers and lymphoma in
the abatacept CDP were consistent with those in a
comparable RA population. These data suggest no new
safety signals with respect to malignancies, which will
continue to be monitored.
Abatacept is the first in a class of agents for the
treatment of rheumatoid arthritis (RA) that
selectively modulates the CD80/CD86 : CD28 co-
stimulatory signal required for T-cell activation.
1
Abatacept has demonstrated efficacy in the treat-
ment of RA.
2–5 Although abatacept has also
demonstrated a favourable safety and tolerability
profile in RA clinical trials, its potential risk for rare
adverse events such as malignancies has not been
addressed in the published literature. When a new
medication becomes available, there is always some
level of concern for the long-term safety of the
medication in a broader patient population.
The risk of malignancy events is of particular
importance in patients who receive immunomo-
dulatory therapies, such as biological disease-
modifying antirheumatic drugs (DMARD).
6 The
current analysis was part of a premarketing risk
assessment that focused on malignancies occurring
in patients in the abatacept clinical development
programme (CDP).
7 To place these observations
into context, we compared the data from abata-
cept-treated patients with data on malignancies
from existing RA cohorts and the general popula-
tion. A recent meta-analysis suggested that RA
patients may be at higher risk of some site-specific
malignancies than the general population, in
particular lymphoma and lung cancer, thus making
RA patients a more appropriate comparison group
than the general population.
8
METHODS
Study design
This observational study examining malignancies
was based on the comparison of cancer occurrence
in patients exposed to abatacept within the CDP,
cancer occurrence in five observational cohorts of
RA patients in Europe and North America and
the occurrence of malignancies in the general
population.
Data sources
Clinical safety data from seven abatacept RA
clinical trials were included in the analyses.
Table 1 presents these studies.
3 9–14
For the RA comparison groups, analyses were
performed on data from five RA cohorts. These
cohorts were derived from the population-based
British Columbia (BC) RA Cohort in Canada, the
Norfolk Arthritis Register (NOAR) in the UK, the
National Data Bank for Rheumatic Diseases (NDB)
in the USA, the Early Rheumatoid Arthritis
Register in Sweden (Sweden ERA) and the
General Practice Research Database (GPRD) in
the UK. Characteristics of these data sources have
been described previously in the literature.
15–19 The
five cohorts were selected for their ability to
provide the patient population of interest (patients
receiving non-biological DMARD only), to provide
age and sex-specific incidence rates (IR) of the
specified outcomes and their ability to complete
the analyses for regulatory filings. Table 2 presents
the characteristics of these databases.
For the general population comparison group,
data on malignancies were obtained from the
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which provides age and sex-specific IR of malignancies for the
US general population.
20 We also reference a recent meta-
analysis paper that evaluated a total of 17 publications
examining standardised incidence ratios (SIR) of malignancy
in RA patients compared with the general population or non-
RA patients who met our inclusion criteria:
8 five studies
reported SIR for total malignancy excluding NMSC;
21–25 nine
for breast cancer;
21 24–31 10 for colorectal cancer;
21 24–32 12 for lung
cancer
21 24–31 33 34 and six for lymphoma.
15 28 35–38
Study subjects
Patients in the abatacept CDP included those who were
randomly assigned to abatacept treatment during the double-
blind period, as well as all patients receiving abatacept during
open-label extension periods. The cumulative abatacept experi-
ence included 4134 abatacept-treated patients representing 8388
person-years of exposure in the seven clinical trials. A total of
1955 patients originated in the abatacept arms of the double-
blind periods of the five core RA studies. Individuals who agreed
to enter the open-label period after completing the double-blind
Table 1 Description of the abatacept clinical trials included in the current analysis
Study name
Study design
Malignancy screening and exclusions
Duration of double-
blind period
(months) Abatacept Placebo
Open-label
extension Study title
IM101100
Phase IIB
Randomised, dose-ranging,
placebo-controlled, double-blind
Mammography requiring further investigation. Complete
evaluation before dosing; history of cancer within the
past 5 years; excluding NMSC cured by local resection
12 220 119 219
IM101101
Phase IIB
Randomised, placebo-controlled,
double blind
Mammography requiring further investigation. Complete
evaluation before dosing; history of cancer within the
past 5 years; excluding NMSC cured by local resection
12 85 36 80
AIM IM101102
Phase III
Randomised, placebo controlled,
double-blind; Abatacept in
inadequate responders to
methotrexate
Subjects with a mammogram that is suspicious for
malignancy; history of cancer within the past 5 years;
excluding NMSC cured by local resection
12 433 219 539
ASSURE
IM101031
Phase III
Randomised, placebo-controlled,
double-blind; Abatacept Study of
Safety in Use with other RA
thErapies
Subjects with a mammogram that is suspicious for
malignancy; history of cancer within the past 5 years;
excluding NMSC cured by local resection
12 959 482 1184
ATTAIN
IM101029
Phase III
Randomised, placebo-controlled,
double-blind; Abatacept Trial in
Treatment of Anti-TNF
INadequate responders
Subjects with a mammogram that is suspicious for
malignancy; history of cancer within the past 5 years;
excluding NMSC cured by local resection
6 258 133 317
Total double-blind 5 core above 1955 989 2689{
ATTEST
IM101043
Abatacept or infliximab versus
placebo, a Trial for Tolerability,
Efficacy and Safety in Treating
RA
History of cancer within the past 5 years; excluding
NMSC cured by local resection
12 156 110 236* (132
abatacept, 104
placebo, 136
infliximab)
ARRIVE
IM101064
Abatacept Researched in
Rheumatoid arthritis patients with
an Inadequate anti-TNF response
to Validate Effectiveness
History of cancer within the past 5 years; excluding
NMSC cured by local resection
6 (open-label) 1046 530
*IM101043, without infliximab arm; {Number represents total number of abatacept exposed patients exposed during both double-blind and open-label; five core trials N = 2689;
overall N = 4134.
NMSC, non-melanoma skin cancer; RA, rheumatoid arthritis; TNF, tumour necrosis factor.
Table 2 Characteristics of data sources used for identification of RA patients included in the epidemiological
analysis
BC NDB GPRD NOAR Sweden ERA
Country Canada USA UK UK Sweden
Data type Administrative data
on physician visits,
hospitalisations and
medications
Patient
questionnaire
Electronic medical
records
Patient
questionnaire and
assessment
Electronic medical
records, patient
assessment
Time period 1996–2001 1998–2003 1987–2001 1990–9 1994–2003
No of RA patients in
cohort
27 710 21 229 38 622 839 3703
Type of cohort Population-based,
prevalent cases
Longitudinal
cohort, prevalent
cases referred by
rheumatologists
Population-based,
prevalent cases
Early RA cohort Early RA cohort
No of DMARD-treated
RA patients
12 337 10 499 14 467 523 3703
DMARD users Prevalent users Prevalent users Prevalent users Incident users Incident users
Case ascertainment ICD-9 codes on
claims and discharge
summaries
Patient-reported
and verified by
medical and
hospital records
OXMIS codes;
codes validated by
an oncologist
ICD-9 codes in
linked medical
records
ICD-10 codes and
verified by linking
to cancer registry
BC, British Columbia RA Cohort; DMARD, disease-modifying antirheumatic drug; GPRD, General Practice Research Database; ICD,
International Classification of Diseases; NDB, National Data Bank for Rheumatic Diseases; NOAR, Norfolk Arthritis Register; RA,
rheumatoid arthritis; Sweden ERA, Sweden Early Rheumatoid Arthritis Register.
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screening was required.
Because 80% of subjects in the abatacept CDP were on
background DMARD therapy during the trials (usually metho-
trexate) and almost all had previous exposure to DMARD, the
most relevant reference group for comparison with the
abatacept patients was considered to be DMARD-treated
patients. Consequently, non-biological DMARD cohorts were
identified from each of the data sources. For the Sweden ERA
cohort, the investigators estimated that 95% of the subjects
received DMARD; therefore, this whole group was included as a
DMARD cohort. In total, 41 529 patients with RA were
included and the demographic characteristics of these patients
are presented by cohort in table 3.
Across all cohorts, most patients (63–72%) were between 45
and 74 years of age and the proportions above and below this
range were low and similar to each other. Patient age at cohort
entry (baseline) was used for the early RA cohort NOAR. For
cohorts with longer follow-up (BC and NDB) and the ERA,
patient age was the age assigned at the time the event occurred.
The BC and NDB cohorts were characterised by a population
that consisted primarily of patients with established RA of
greater than 5 years duration, 60% and 70% of the subjects,
respectively, whereas the early RA cohorts followed patients
from disease onset. Mean patient-years of follow-up across RA
DMARD cohorts ranged from 3.3 to 7.9 patient-years.
Case ascertainment
Prespecified outcomes included total malignancy excluding non-
melanoma skin cancer (NMSC) and the four site-specific
malignancies of breast cancer, colorectal cancer, lung cancer
and lymphoma. Breast, lung and colorectal cancers were
included because they represent the three most common cancer
sites in women (in the USA). Lymphoma was included as it has
consistently been shown to be elevated in RA patients.
9–18 As
outlined in table 2, malignancies for this analysis were identified
by International Classification of Diseases (ICD)-9 and ICD-10
diagnostic codes in the BC, NOAR and the Sweden ERA data
sources, as reported within the registries or through linkage to
cancer registers (Sweden ERA). OXMIS and Read codes recorded
in the medical record were used to identify malignancies in the
GPRD analyses. In the NDB, malignancies were identified from
semi-annual questionnaires completed by RA patients who
were subsequently validated by physicians. For patients in the
abatacept CDP, malignancies were identified from all adverse
event reports and validated through special event forms; events
were included regardless of their relationship to the study drug.
Analyses
Baseline demographics and clinical characteristics were com-
puted using descriptive statistics for continuous or categorical
variables as appropriate. In the abatacept clinical experience,
exposure to abatacept and incidence of malignancy were
counted from the start of therapy until the first event or end
of treatment period plus 56 days, whichever occurred first.
Rates were computed for the double-blind period, as well as the
cumulative double-blind and open-label study period. In the RA
DMARD observational cohorts, person-time and incidence of
malignancy were calculated from the first recorded non-
biological DMARD exposure until the first event or the end of
follow-up, whichever occurred first. The IR for each outcome of
interest in the RA DMARD cohorts were standardised to the
age (10-year interval) and sex distribution of the abatacept
clinical trial experience.
To estimate the relative risk of malignancy in the abatacept
CDP relative to that in each of the five RA DMARD cohorts and
the US general population, SIR were calculated, dividing the
observed numbers of malignancy cases in the abatacept trial
Table 3 Baseline demographics and clinical characteristics of abatacept clinical trial patients and RA
DMARD cohorts included in the epidemiological analyses
Abatacept
Clinical Trial
Program
(N = 4134)
BC
(N = 12 337)
NDB
(N = 10 499)
GPRD
(N = 14 467)
NOAR
(N = 523)
Sweden ERA
(N = 3703)
Age, years, n (%)
,20 4 (0.1) 214 (2) 13 (0.1) 34 (0.2) 3 (1) 29 (1)
20–44 1011 (24) 2874 (23) 1429 (14) 2856 (20) 106 (20) 753 (20)
45–64 2435 (59) 5148 (42) 4870 (47) 6998 (48) 246 (47) 1624 (44)
65–74 553 (13) 2692 (22) 2716 (26) 3375 (23) 120 (23) 797 (22)
>75 131 (3) 1409 (11) 1438 (14) 1204 (8) 48 (9) 500 (14)
Female, n (%) 3323 (80) 8936 (72) 7971 (76) 10 284 (71) 357 (68) 2589 (70)
Duration of RA, years,
n (%)
,5 1353 (33) 4890 (40) 2726 (29)
* NA 523 3703
5–10 1192 (29) 4206 (34) 1902 (20)
* NA 0 0
.10 1586 (38) 3241 (26) 4716 (50)
* NA 0 0
Concomitant
medications, n (%)
{
Oral corticosteroids 2657 (64) 8121 (66) NA 6902 (48) 194 (37) NA
NSAID 3113 (75) 11 001 (89) 6820 (65) 13 656 (94) 416 (80) NA
Total follow-up, years
Mean 2.1 4.9 3.3 3.7 7.9 3.6
Median 1.8 6.0 2.5 4.1 9.3 NA
*Rheumatoid arthritis (RA) duration was not collected for every subject in the NDB; therefore, n = 9344 for this variable.
{Use of
concomitant medications at baseline is presented for the abatacept trial population, whereas use during follow-up is presented for
the RA cohorts (when available).
BC, British Columbia RA Cohort; DMARD, disease-modifying antirheumatic drug; GPRD, General Practice Research Database; NDB,
National Data Bank for Rheumatic Diseases; NOAR, Norfolk Arthritis Register; NSAID, non-steroidal anti-inflammatory drugs;
Sweden ERA, Sweden Early Rheumatoid Arthritis Register.
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were calculated by multiplying the cancer rates in the five RA
cohorts by the observed person-years at risk, stratified by sex
and 10-year age group. Furthermore, we computed a summary
SIR estimate (and 95% CI) combining the SIR from the five
DMARD cohorts based on the meta-analysis method of
DerSimonian and Laird.
39 This method uses a random effects
model that considers both within-study and between-study
variation by incorporating the heterogeneity of effects in the
overall analysis.
To determine if our results differ from those in the published
literature, the SIR obtained were compared with those
published in studies evaluating non-RA or general population
malignancy incidence to RA populations.
For all SIR, 95% CI were calculated using the Wilson and
Hilferty approximation. Statistical analyses were performed
using the SAS software package.
RESULTS
The numbers and rates of malignancies in the abatacept CDP
are shown in table 4.
During the double-blind period, 10 malignancies were
reported in the 1955 patients with 1688 person-years of
follow-up receiving abatacept and five malignancies in the 989
patents with 794 person-years of follow-up randomly assigned
to placebo. During the double-blind period, lung and breast
cancers were the most frequently reported solid malignancies in
the abatacept and placebo-treated patients, respectively.
Four cases of lung cancer were identified in the abatacept
patients and none in the placebo group during the double-blind
period. The cases of lung cancer presented with no atypical
clinical features; all patients were over 60 years of age and three
of the four subjects were heavy smokers. There was no
predominant tumour type. Two of the cases were in subjects
who had exposure to abatacept of 100 days or less (29 days and
100 days). A third subject had a small apical lung nodule that
went undetected on the pretreatment chest radiograph.
There were two cases of breast cancer in the placebo group
and one case in patients receiving abatacept. All three cases were
identified at the annual protocol-required mammogram at one
year. Two of the cases (one abatacept and one placebo) were
noted to have normal mammography at baseline. One case in
the placebo group did not report baseline mammography
results. No cases of colorectal cancer were reported in either
group. There was one case of lymphoma in the abatacept group
and none in the placebo group. IR were computed and are
presented in table 4.
Table 4 Incidence of malignancies in the abatacept clinical trial experience
Placebo DB*{ Abatacept DB*{
Abatacept 5 core RA
RCT{ (DB+OL){
Abatacept cumulative1
(DB+OL){
No of patients 989 1955 2689 4134
No of person-years of
follow-up
794 1688 7282 8388
Total malignancies
(excluding NMSC)
51 04 65 1
0.63 (0.26 to 1.5) 0.59 (0.32 to 1.1) 0.63 (0.46 to 0.84) 0.61 (0.45 to 0.80)
Breast cancer 2 1 5 7
0.25 (0.06 to 1.01) 0.06 (0.01 to 0.43) 0.07 (0.02 to 0.16) 0.08 (0.03 to 0.17)
Colorectal cancer 0 0 2 2
0.03 (0.00 to 0.10) 0.02 (0.00 to 0.09)
Lung cancer 0 4 13 13
0.24 (0.09 to 0.64) 0.18 (0.10 to 0.31) 0.15 (0.08 to 0.27)
Lymphoma 0 1 4 5
0.06 (0.01 to 0.43) 0.05 (0.01 to 0.14) 0.06 (0.02 to 0.14)
Unless otherwise indicated, values represent number of cancer cases and incidence rates per 100 person-years (95% CI). *DB,
double blind; randomisation 2 : 1 abatacept to placebo. {Includes the five core rheumatoid arthritis (RA) studies: ATTAIN,
ASSURE, AIM and two phase II studies. {OL, open label, December 2006 data lock. 1Includes the five core RA studies and the
ATTEST and ARRIVE studies.
NMSC, non-melanoma skin cancer; RCT, randomised controlled trial.
Table 5 Incidence of malignancies in the RA DMARD cohorts*
BC NDB GPRD NOAR Sweden ERA
Total malignancies (excluding
NMSC)
1274 NA
{ 472 30 148
1.77 (1.51 to 2.08) 0.67 (0.51 to 0.87) 0.73 (0.56 to 0.93) 0.71 (0.55 to 0.92)
Breast cancer 205 156 94 4 13
0.34 (0.24 to 0.49) 0.28 (0.19 to 0.42) 0.16 (0.09 to 0.28) 0.14 (0.08 to 0.25) 0.11 (0.06 to 0.21)
Colorectal cancer 139 52 40 2 20
0.14 (0.08 to 0.24) 0.06 (0.03 to 0.15) 0.05 (0.02 to 0.13) 0.05 (0.02 to 0.13) 0.06 (0.02 to 0.14)
{
Lung cancer 218 116 109 4 23
0.26 (0.17 to 0.39) 0.12 (0.07 to 0.22) 0.14 (0.08 to 0.25) 0.09 (0.04 to 0.18) 0.13 (0.07 to 0.23)
Lymphoma 94 35 41 3 11
0.11 (0.06 to 0.21) 0.08 (0.04 to 0.17) 0.06 (0.02 to 0.14) 0.07 (0.03 to 0.16) 0.06 (0.02 to 0.14)
Values represent numbers of incident cancer cases and incidence rates (IR) per 100 person-years (95% CI). *Rates adjusted to the age and sex distribution of the abatacept clinical
trial patients.
{This outcome was not available for the NDB.
{The Sweden ERA cohort for the colorectal cancer analysis consists of 4295 patients rather than the 3703 used for the
other malignancies.
BC, British Columbia RA Cohort; DMARD, disease-modifying antirheumatic drug; GPRD, General Practice Research Database; NDB, National Data Bank for Rheumatic Diseases;
NMSC, non-melanoma skin cancer; NOAR, Norfolk Arthritis Register; RA, rheumatoid arthritis; Sweden ERA, Sweden Early Rheumatoid Arthritis Register.
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exposure analysis, a total of 4134 patients with 8388 person-
years of follow-up has been exposed to abatacept. IR of
malignancies in the double-blind and cumulative periods were
relatively similar; however, the rate of lung cancer was slightly
lower in the cumulative study period. The age and sex-adjusted
IR of total malignancies excluding NMSC in the abatacept
clinical trials was 0.61 per 100 person-years (95% CI 0.45 to
0.80). This rate was similar to the age and sex-adjusted IR
reported in the RA DMARD cohorts, except for the BC cohort,
in which it was lower (table 5).
Overall, except for the BC cohort in which higher IR were
observed, there was considerable overlap of the 95% CI among
the RA cohorts when compared with abatacept. The abatacept
Figure 1 Standardised incidence ratios (SIR) of malignancies in the abatacept cumulative study periods compared with the observational rheumatoid
arthritis disease-modifying antirheumatic drug cohorts. Values represent SIR and 95% CI. (A) Total malignancy (excluding non-melanoma skin cancer);
(B) Breast cancer; (C) Colorectal cancer; (D) Lung cancer; (E) Lymphoma. BC, population-based British Columbia RA Cohort; GPRD, General Practice
Research Database; NDB, National Data Bank for Rheumatic Diseases; NOAR, Norfolk Arthritis Register; RCT, randomised controlled trial; Sweden ERA,
Sweden Early Rheumatoid Arthritis Register.
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range of IR in the RA DMARD cohorts (0.11–0.34/100 person-
years). The abatacept IR of lung cancer (0.15/100 person-years;
95% CI 0.08 to 0.27) and lymphoma (0.06/100 person-years;
95% CI 0.02 to 0.14) were within the range of IR from the five
RA cohorts (0.09–0.26/100 person-years and 0.06–0.11/100
person-years for lung cancer and lymphoma, respectively).
Figure 1 presents the SIR representing the relative risk of total
malignancy (excluding NMSC) with abatacept compared with
each of the RA cohorts. The SIR are somewhat reduced
compared with the BC cohort, which had a higher incidence
of cancers. The summary SIR comparing the rate of total
malignancies (excluding NMSC) in the abatacept CDP with the
pooled IR from the RA cohorts was 0.68 (95% CI 0.37 to 1.26),
indicating that the overall risk of cancer was not significantly
increased in abatacept-treated patients compared with RA
patients treated with DMARD. Regarding specific types of
cancers, the risk of breast cancer with abatacept may be reduced
(summary SIR 0.42, 95% CI 0.18 to 1.00); however, women
with RA were screened for prevalent breast cancer with
mammography before enrollment in the double-blind abatacept
studies. The summary SIR estimate for colorectal cancer was
0.33 (95% CI 0.08 to 1.44). The risk of lung cancer with abatacept
was not significantly increased compared with any of the cohorts,
althoughthepointestimateswereabove1inthecomparisonwith
four of the five cohorts; the summary SIR estimate was 1.07 (95%
CI 0.55 to 2.07). There appeared to be general risk parity for
lymphoma between abatacept and the RA DMARD cohorts,
although confidence intervals were wide. The overall summary
SIR for lymphoma was 0.89 (95% CI 0.36 to 2.15).
For the comparison of the abatacept clinical trial malignancy
experience with the general population, the calculated SIR
comparing cancer IR in RA patients treated with abatacept with
IR in the general population, from the SEER cancer registry,
were 0.82 (95% CI 0.61 to 1.08) for total malignancy excluding
NMSC, 0.41 (95% CI 0.17 to 0.85) for breast cancer, 0.32 (95%
CI 0.04 to 1.16) for colorectal cancer, 1.51 (95% CI 0.80 to 2.59)
for lung cancer and 2.17 (95% CI 0.70 to 5.07) for lymphoma.
These SIR fell within the range of SIR published in studies
comparing malignancy in RA samples with the general
population (fig 2).
15 21 24–38
DISCUSSION
This study provides context for the malignancy experience in
patients treated with abatacept. The data presented suggest
that the observed incidence of total malignancy (excluding
NMSC) and of four site-specific malignancies (breast, colorectal,
lung and lymphoma) in patients within the abatacept CDP is
largely consistent with what may be expected based on cohorts
of RA patients treated with non-biological DMARD. Similarly,
the SIR estimates comparing the abatacept trial experience with
that in the general population were similar to SIR comparing
other RA cohorts with the general population.
The potential association between malignancies and RA has
previously been reviewed.
84 0Most studies suggest that the risk
of total or solid malignancies in patients with RA is not
substantially different compared with the general population or
individuals without RA;
21–30 32 36 38 however, data suggest that
RA patients are at higher risks of lymphoma and lung cancer.
8
Whereas the incidence of breast cancer may be slightly
decreased in patients with RA,
24 26 29 several studies found no
significant difference when compared with the general popula-
tion.
25 27 28 30 31 A number of investigators have observed a
decreased risk of colon or rectum cancer associated with RA,
which may result from the long-term use of non-steroidal anti-
inflammatory drugs (NSAID) or cyclooxygenase-2 selective
inhibitors.
24–29 32 Given these malignancy differences in RA
patients, an RA cohort represents a more appropriate compara-
tor for evaluating the malignancy risk of specific RA interven-
tions than the general population.
A number of recent studies has examined malignancy risk in
RA patients in the context of medication use. In their meta-
analysis of nine clinical trials of infliximab or adalimumab,
Bongartz et al
6 suggested an increased risk of malignancy in the
treatment arms compared with placebo. However, several large
epidemiological studies found no increased risk in overall
malignancy or solid malignancy associated with anti-tumour
necrosis factor (TNF) use compared with non-use or metho-
trexate.
24 26 31 38 The majority of studies examining the effect of
medication use on malignancy in RA have focused on
lymphoma. Epidemiological studies have not documented a
significantly elevated risk of lymphoma with anti-TNF use
compared with non-use or methotrexate.
15 31 35 38 Several studies,
Figure 2 Standardised incidence ratios
(SIR) of malignancies in the abatacept
cumulative study periods compared with
the general population (Surveillance
Epidemiology and End Results (SEER)).
The lines indicate the SIR point estimates
and 95% CI for abatacept compared with
the general population (SEER). The
diamonds represent SIR reported in the
literature that compare rheumatoid
arthritis (RA) patients with non-RA
patients or general populations. *One
study had no observed cases of lung
cancer; the SIR is not presented in the
figure. RCT, randomised controlled trial.
Extended report
1824 Ann Rheum Dis 2009;68:1819–1826. doi:10.1136/ard.2008.097527however, have linked azathioprine use with lymphoma
41 42 and
the data on methotrexate and lymphoma have been mixed.
43 44
This study has several strengths, including comparisons with
a diversity of relevant RA populations from different sources as
well as with the general population. A total of five large RA
cohorts was identified and used to obtain a range of reference
rates. When conducting pharmacoepidemiological studies, it has
been recommended that at least two cohorts be evaluated to
establish the extent of reproducibility.
45 The resulting variation
in the IR among the cohorts provides a more useful range of
estimates for comparison than a single cohort IR. In our study,
despite the geographical differences and the differences in
ascertainment methods, the ranges of age and sex-adjusted IR
were relatively narrow among the various RA cohorts, indicat-
ing good reproducibility of our results. Another strength of the
study was the choice of comparison group. We were able to
include in the study, as a reference group, only those patients
treated with DMARD from the respective RA cohorts. Given
that DMARD comprised the background therapy in all
abatacept-treated patients in the trials, this constitutes an
appropriate reference group for comparing the risk of malig-
nancy.
This study has several potential limitations, including those
inherent in the study design. The data collected and analysed
from the RA cohorts were not primarily collected for this type
of study. The limitations associated with the use of external
control groups include but are not limited to differences in
management and diagnoses of RA, the inclusion of both
prevalent and new users of DMARD agents, differences in the
ascertainment and verification of outcomes, length of follow-
up, validity of RA diagnosis and severity of disease. We
acknowledge that these variables may be different among the
RA cohorts. Although the abatacept population appeared to be
demographically similar to the cohorts, clinical trial patients are
inherently different. The abatacept CDP enrolled mainly
prevalent, stable non-biological DMARD users who have an
inadequate response to their current therapy; thereby implying
more severe disease in these patients. The RA cohort popula-
tions were a diverse group of both prevalent and new non-
biological DMARD users. The RA cohort populations are
potentially more stable in that this population had to be on a
non-biological DMARD throughout follow-up without the
addition of a biological therapy. However the non-biological
DMARD treatment in these groups could be altered during
follow-up such that non-biological DMARD therapy could be
increased, decreased, or another non-biological treatment could
be added to the current regimen all together. Trial patients may
be monitored more closely for adverse events, which might
overestimate our calculated SIR. However, some of the cohorts
have prespecified observation times for patients enrolled in the
registry (eg, NOAR). Malignancy screening for breast cancer
with mammograms before entry in the trials may have resulted
in a lower incidence of breast cancer in the abatacept CDP. The
exclusion of patients with a history of cancer within the past
5 years of study entry suggests that enrolled patients are
potentially healthier, resulting in a lower overall incidence of
cancer. It is not uncommon for clinical trials to exclude patients
who may be predisposed to cancer. There is also the concern of
latency when evaluating malignancy outcomes. We were not
able to adjust for potential confounders such as severity of
disease, smoking, ethnicity, co-morbidities and the use of non-
DMARD medications (ie, NSAID, corticosteroids) due to
unavailability of data on these variables in most external
cohorts. Finally, each of the databases used in this study may be
associated with specific limitations, such as uncertainty
surrounding diagnostic accuracy in administrative claims
databases (eg, BC), small cohort size (eg, NOAR), the use of
self-reporting (eg, NDB), etc. However, these individual limita-
tions were minimised by the use of multiple cohorts, resulting
in a range of references that nevertheless provided relatively
consistent results.
In conclusion, external observational data provide useful
information when long-term comparator data from randomised
controlled trials are not available. Although differences in
selection, surveillance and verification exist between clinical
trials and observational cohorts, a range of estimates provides
useful context for the evaluation of the abatacept long-term
clinical trial experience. These data add to the continuing body
of evidence evaluating the safety of abatacept and suggest that
the observed number of malignancies is within the range of
expected malignancies based on RA cohorts on a background of
non-biological DMARD treatment. The overall safety of
abatacept with respect to malignancies will continue to be
monitored as part of a post-marketing surveillance programme.
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